|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
At the protein level, 15 of 22 of the DLBCL samples (68%) showed strong staining for the CDK2 protein, compared with five of 21 of FL samples (24%).
|
16704435 |
2006 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma.
|
9591637 |
1998 |
|
Hodgkin Disease
|
0.330 |
Biomarker
|
disease |
BEFREE |
The CDKN2 gene is also inactivated in some patients with non-Hodgkin's lymphomas, adult T-cell leukemias, and lymphoid blastic crisis of chronic myelogenous leukemias.
|
9086436 |
1997 |
|
Hodgkin Disease
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
We present an allelotype analysis of 35 cases of non-Hodgkin lymphomas and normal pairs using four microsatellite markers that flank the region occupied by the CDKN2 gene locus at 9p21.
|
9309120 |
1997 |
|
Hodgkin Disease
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
To determine if CDKN2 or another closely related gene on 9p is the target of 9p deletions in ALL and other hematologic malignancies, we analyzed 20 primary patient samples (13 ALL, 2 acute myeloid leukemias [AML], and 5 non-Hodgkin's lymphomas [NHL]) with 9p rearrangements using Southern blot analysis, fluorescence in situ hybridization (FISH), and single-strand conformation polymorphism (SSCP) for alterations of CDKN2.
|
7544647 |
1995 |
|
Hodgkin Disease
|
0.330 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Glomerulonephritis, Membranoproliferative
|
0.200 |
Biomarker
|
disease |
RGD |
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis.
|
17893107 |
2007 |
|
Liver Cirrhosis, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Expression patterns of cytokine, growth factor and cell cycle-related genes after partial hepatectomy in rats with thioacetamide-induced cirrhosis.
|
16534847 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting CDK2 in cancer: challenges and opportunities for therapy.
|
31839441 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CDK2 and its regulatory subunits are deregulated in many human cancers and there is emerging evidence suggesting CDK2 inhibition elicits antitumor activity in a subset of tumors with defined genetic features.
|
31839441 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that GY-1 showed good anti-liver cancer activity with the IC<sub>50</sub> of 84.7 μmol/L in vitro, inhibited tumor growth in vivo with dose-dependent, and GY-1 could arrest the growth of hepatoma cells in the S phase and induced apoptosis in hepatoma cells, down-regulated the expression of C-myc, CDK2 and CyclinE, and up-regulate p53.
|
31797046 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CDK2 destabilizes tumor suppressor C/EBPα expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
|
31692040 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, we discovered that p-CDK2 protein was expressed in both cytoplasmic and nucleus in salivary ACC tissues, which was higher than that in normal salivary tissues, indicating that agents targeting CDK2 may be potential therapeutic strategies against this type of tumor.
|
31529315 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Treatment with alsterpaullone, an inhibitor of the CDK2 complex, resulted in a survival benefit and suppressed tumor invasion in a mouse model of LPDs.
|
31743514 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting CDK2 in cancer: challenges and opportunities for therapy.
|
31839441 |
2020 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show here that Cdk2 has an essential role in palbociclib antitumor effect against bladder cancers.
|
30772267 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western Blot was performed to detect the expressions of AMPKα, Yap1, CCND1, CCNE1/2 and CDK2/4/6 in the metformin-treated BLCA cell lines.
|
31455378 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, a molecular docking study was employed to determine the binding modes against aromatase cytochrome P450 (CYP19), cyclin-dependent kinase 2 (CDK2), and B-cell lymphoma (BCL-2) proteins, which are major proteins involved in the pathogenesis of cancer.
|
30613863 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Docking investigations into Cyclin-dependent kinase 2 (CDK-2) enzyme, a potential target for cancer medication, were also reported showing the possible binding interaction into the enzyme active site to support their activity behavior.
|
30864522 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Enzyme docking investigation was performed into cyclin-dependent kinase 2 (CDK2); a potential target for cancer medication.
|
30599108 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin Dependent Kinases CDKs unpredictable activity has been accounted for a wide assortment of human malignancies, so it might be conceivable to design pharmacologically relevant ligands that go about as specific and potent inhibitors of CDK2 action.
|
31513938 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we suggest that the compound (PubChem ID 101874157) would be a promising scaffold to be further exploited as a potential inhibitor of CDK2 for therapeutic management of cancer after required validation.
|
31847444 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We use this abundance of data to analyze the essential features responsible for the inhibition of CDK2 and its function in cancer and senescence.
|
30516105 |
2019 |